Hem A Patient in SIG-001 Trial Had Scarring in Delivery Spheres

Hem A Patient in SIG-001 Trial Had Scarring in Delivery Spheres

313099

Hem A Patient in SIG-001 Trial Had Scarring in Delivery Spheres

In the first clinical trial of the experimental therapy SIG-001 for hemophilia A, one patient developed scarring in the spheres used to deliver the therapy that rendered the treatment ineffective, its developer, Sigilon Therapeutics, announced. The Phase 1/2 trial was put on hold by the U.S. Food and Drug Administration (FDA) in July after the agency was informed by Sigilon of safety concerns in a treated patient. “Patients’ safety and welfare are our highest priority. We are…

You must be logged in to read/download the full post.